BMS at the 62nd ASH Annual Meeting and Exposition

Critical research driving progress for people with blood cancers

Intended for scientific audiences only.

The American Society of Hematology Annual Meeting and Exposition (ASH) is the premier event in malignant and non-malignant hematology, and despite this year’s challenges, we remain ever-committed to sharing the latest advances and providing continued support as we continue to navigate the COVID-19 pandemic. We look forward to highlighting the depth and diversity of our hematology development program and potential new advances for people living with a range of blood cancers.

Our Data at ASH

Read more about our key data being presented at ASH.

Learn more about BMS’ presentations at ASH 2020
Check out the BMS ASH Virtual Exhibit

Our Science   

We are working every day to advance blood cancer treatments that have transformational potential. Learn about our recent advances and what we have on the horizon.

Building on Today’s Science to Research Medicines of Tomorrow  >

As a scientific research community, our work for people living with cancer is never done. Read about two examples of the research Bristol Myers Squibb is elevating to advance next-generation approaches in oncology and hematology.

Advancing Acute Myeloid Leukemia Research Through Epigenetics  >

Instead of killing the cell, hypomethylating agents, or HMAs, alter the signaling process by re-expressing genes to work properly again. Learn more about the treatment of AML through epigenetics.

Protein Homeostasis 101: A Q&A With Josh Hansen  >

Years before Josh Hansen, director of chemistry at Bristol Myers Squibb’s San Diego R&D site,  found his calling in biopharma researching protein degradation, he had his sights set on a career in education. Read more about the important science being done in Josh’s lab.

Our Commitment   

We are committed to improving the lives of patients and raising awareness of hard-to-treat blood cancers. Learn more here.

Raising Awareness about Blood Cancers: A Diverse and Complex Group of Diseases  >

Learn how Bristol Myers Squibb, in collaboration with advocacy partners, is committed to providing education, resources and support to people with blood cancers.

Addressing Barriers to Clinical Trial Participation and Clinical Trial Diversity During COVID-19 and Beyond  >

Hear from Chief Medical Officer Samit Hirawat, M.D., on how Bristol Myers Squibb has helped patients overcome barriers to clinical trial participation and advanced its R&D pipeline during the global pandemic.

The Expanding Prevalence of Beta-thalassemia  >

Beta-thalassemia is a blood disorder, with more than 60,000 infants born worldwide with the disease each year. However, unless you live in Asia, India, the Middle East or the Mediterranean where beta-thalassemia is most prevalent, you may never have heard of this inherited blood disorder that disrupts the body’s ability to make hemoglobin.

What Is Myelodysplastic Syndrome? Is MDS a Form of Cancer?  >

Possibly the only thing more frightening than being diagnosed with cancer is learning you have a form of the disease you’ve never heard of. Patients with MDS— a little-known blood cancer— are searching for new Multidysplastic Syndrome treatment options.

Our Dedication to Advancing Cell Therapy, A Novel Personalized Medicine

Cell therapy, which includes therapies comprised of cells that are injected, implanted or grafted to treat disease, and use engineered cells to unlock new potential in the fight against cancer, is one of several key areas of research at Bristol Myers Squibb. Learn more about our dedication to cell therapies and personalized medicine here.

Cell Therapy  >

Learn more about the science behind cell therapy.

Cell Therapy: Looking to the Future of CAR T  >

Fulfilling the promise of cell therapy requires continued innovation, which is why researchers at Bristol Myers Squibb are relentlessly pursuing a multitude of diverse, next-generation approaches in cell therapy. Learn more about how Bristol Myers Squibb is investing in cell therapy research and using translational data to advance the science for patients.

In Cellular Therapy, Patients and Physicians Are Always Learning  >

Kristen Hege, Senior Vice President of Early Clinical Development, Hematology/Oncology & Cell Therapy, shares how patients and physicians can stand to learn from each other, especially with novel treatments like CAR T cell therapy, where practical information is still being refined. Read more about Kristen’s experience and ongoing pursuit to empower her patients.


Our research at ASH this year spans multiple myeloma, lymphoma and myeloid diseases, and multiple therapeutic modalities. Learn more about some of them below.

Protein Degradation Fact Sheet 

Understand the process of cellular protein degradation. 

Disease State Infographics

Download infographic resources on different types of blood cancers.